-
公开(公告)号：US09764041B2
公开(公告)日：2017-09-19
申请号：US14390734
申请日：2012-04-04
申请人： Keisuke Ishii , Katsuyuki Mitomo , Katsushi Kouda , Fumiko Nomura , Yoko Kayukawa , Tadashi Matsuura
发明人： Keisuke Ishii , Katsuyuki Mitomo , Katsushi Kouda , Fumiko Nomura , Yoko Kayukawa , Tadashi Matsuura
IPC分类号： A61K39/395 , A61K47/48 , C07K16/28 , C07K16/30
CPC分类号： A61K47/6855 , A61K47/6851 , A61K47/6879 , A61K47/6889 , C07K16/28 , C07K16/30 , C07K16/3015 , C07K2317/565
摘要： It is an object of the present invention to provide a drug conjugate comprising an anti-CDH3 antibody that efficiently kills cancer cells expressing CDH3. According to the present invention, there is provided an immune complex formed by binding an antibody against CDH3 or a fragment thereof having CDH3 binding ability to a chemotherapeutic agent.
-
公开(公告)号：US20130071324A1
公开(公告)日：2013-03-21
申请号：US13578462
申请日：2011-02-09
申请人： Akihiro Hino , Akio Nagano , Masahiko Watanabe , Tadasi Matsuura , Hirokazu Satoh , Fumiko Nomura , Katsuyuki Mitomo
发明人： Akihiro Hino , Akio Nagano , Masahiko Watanabe , Tadasi Matsuura , Hirokazu Satoh , Fumiko Nomura , Katsuyuki Mitomo
CPC分类号： A61K51/1027 , A61K51/1093 , A61K51/1096 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K16/46 , C07K2317/24 , C12N15/02 , C12N15/85
摘要： An object of the present invention is to provide a radioactive metal anti-cadherin antibody which is highly accumulated specifically in cancer tissue. Another object is to provide a cancer therapeutic agent having high anti-cancer effect and safety and a cancer diagnostic agent. The radioactive metal-labeled anti-cadherin antibody is obtained by binding a radioactive metallic element to an anti-cadherin antibody via a metal-chelating reagent.
摘要翻译： 本发明的目的是提供一种在癌组织中高度积累的放射性金属抗钙粘蛋白抗体。 另一个目的是提供具有高抗癌作用和安全性的癌症治疗剂和癌症诊断剂。 放射性金属标记的抗钙粘蛋白抗体是通过金属螯合剂将放射性金属元素与抗钙粘蛋白抗体结合而获得的。
-
公开(公告)号：US09598496B2
公开(公告)日：2017-03-21
申请号：US14116714
申请日：2012-05-07
申请人： Yoshikazu Kurosawa , Kazuhiro Morishita , Lilin Zhang , Gene Kurosawa , Katsuyuki Mitomo , Yukio Sudo , Fumiko Nomura , Yoshinori Ukai
发明人： Yoshikazu Kurosawa , Kazuhiro Morishita , Lilin Zhang , Gene Kurosawa , Katsuyuki Mitomo , Yukio Sudo , Fumiko Nomura , Yoshinori Ukai
IPC分类号： A61K39/395 , C07K16/28 , C07K16/30
CPC分类号： C07K16/30 , C07K16/2881
摘要： An object of present invention is to provide a complete human anti-human TfR antibody, which specifically recognizes human TfR, inhibits the survival or growth of cancer cells that highly express TfR, and has no immunogenicity to humans. The present invention provides an antibody which specifically reacts with human TfR, wherein the antibody comprises any one of the amino acid sequences shown in SEQ ID NOS: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, and 115-117, as each of a heavy chain first complementarity determining region (VH CDR1), a heavy chain second complementarity determining region (VH CDR2), and a heavy chain third complementarity determining region (VH CDR3).
-
公开(公告)号：US09127061B2
公开(公告)日：2015-09-08
申请号：US14129049
申请日：2012-06-19
申请人： Lilin Zhang , Katsuyuki Mitomo , Katsushi Kouda , Yoko Kayukawa
发明人： Lilin Zhang , Katsuyuki Mitomo , Katsushi Kouda , Yoko Kayukawa
CPC分类号： C07K16/28 , A61K39/395 , A61K2039/505 , C07K16/46 , C07K2317/24 , C07K2317/54 , C07K2317/732 , C12N5/10 , C12N15/09 , G01N33/53 , G01N33/57484
摘要： It is an object to provide a recombinant antibody that is an anti-CDH3 antibody having cytotoxicity on CDH3-expressing cells, which is anticipated to have fewer side effects than antibodies derived from animals other than humans and to maintain its therapeutic effects for a long period of time. The present invention provides a recombinant antibody which specifically reacts with an epitope existing in the amino acids at positions 108 to 131 or at positions 551 to 654 of the amino acid sequence shown in SEQ ID NO: 38 that is the extracellular region of human CDH3, and has cytotoxicity against CDH3-expressing cells.
摘要翻译： 本发明的目的是提供一种抗CDH3抗体的重组抗体，其具有对表达CDH3的细胞具有细胞毒性的抗CDH3抗体，其预期比来自除人以外的动物的抗体具有较少的副作用并长期保持其治疗效果 的时间。 本发明提供了与存在于SEQ ID NO：38所示氨基酸序列的位置108至131或位于第551至654位的表位存在的表位的重组抗体，所述氨基酸序列是人CDH3的胞外区， 并对CDH3表达细胞具有细胞毒性。
-
公开(公告)号：US20140114054A1
公开(公告)日：2014-04-24
申请号：US14116714
申请日：2012-05-07
申请人： Yoshikazu Kurosawa , Kazuhiro Morishita , Lilin Zhang , Gene Kurosawa , Katsuyuki Mitomo , Yukio Sudo , Fumiko Nomura , Yoshinori Ukai
发明人： Yoshikazu Kurosawa , Kazuhiro Morishita , Lilin Zhang , Gene Kurosawa , Katsuyuki Mitomo , Yukio Sudo , Fumiko Nomura , Yoshinori Ukai
IPC分类号： C07K16/30
CPC分类号： C07K16/30 , C07K16/2881
摘要： An object of present invention is to provide a complete human anti-human TfR antibody, which specifically recognizes human TfR, inhibits the survival or growth of cancer cells that highly express TfR, and has no immunogenicity to humans. The present invention provides an antibody which specifically reacts with human TfR, wherein the antibody comprises any one of the amino acid sequences shown in SEQ ID NOS: 1-3, 7-9, 13-15, 19-21, 25-27, 31-33, 37-39, 43-45, 49-51, 55-57, 61-63, 67-69, 73-75, 79-81, 85-87, 91-93, 97-99, 103-105, 109-111, and 115-117, as each of a heavy chain first complementarity determining region (VH CDR1), a heavy chain second complementarity determining region (VH CDR2), and a heavy chain third complementarity determining region (VH CDR3).
摘要翻译： 本发明的目的是提供一种完全人抗TfR抗体，其特异性识别人TfR，抑制高表达TfR的癌细胞的存活或生长，并且对人类没有免疫原性。 本发明提供与人TfR特异性反应的抗体，其中所述抗体包含SEQ ID NO： 31-33,37-39,43-45,49-51,55-57,61-63,67-69,73-75,79-81,85-87,91-93,97-99,103- 105，109-111和115-117，作为重链第一互补决定区（VH CDR1），重链第二互补决定区（VH CDR2）和重链第三互补决定区（VH CDR3） 。
-
6.发明申请GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA VIRUS SPIKE PROTEIN 审中-公开通过使用用RNA病毒或DNA病毒SPIKE蛋白质刺激的宿主细胞将基因转移到空中上皮细胞中公开(公告)号：US20090162320A1
公开(公告)日：2009-06-25
申请号：US12091646
申请日：2006-10-27
CPC分类号： C12N15/86 , A61K9/0043 , A61K38/162 , A61K38/1709 , A61K38/177 , A61K48/00 , C07K14/4712 , C12N5/0688 , C12N7/00 , C12N2510/00 , C12N2740/15033 , C12N2740/15043 , C12N2740/15045 , C12N2810/6072 , C12N2810/609
摘要： The present inventors successfully introduced genes into stem cells of airway epithelial tissues using simian immunodeficiency virus vectors pseudotyped with F and HN, which are envelope glycoproteins of Sendai virus. Gene transfer into airway epithelial tissue stem cells using a vector of the present invention is useful for gene therapy of genetic respiratory diseases such as cystic fibrosis. Furthermore, it is possible to select respiratory organs such as the lungs as production tissues for providing proteins that are deficient due to genetic diseases.
摘要翻译： 本发明人成功地将基因引入气道上皮组织的干细胞，其中使用以F和HN为假型的猿免疫缺陷病毒载体，其是仙台病毒的包膜糖蛋白。 使用本发明的载体将基因转移到气道上皮组织干细胞中可用于遗传呼吸系统疾病如囊性纤维化的基因治疗。 此外，可以选择诸如肺的呼吸器官作为用于提供由于遗传疾病而缺陷的蛋白质的生产组织。
-
公开(公告)号：US08815211B2
公开(公告)日：2014-08-26
申请号：US13578462
申请日：2011-02-09
申请人： Akihiro Hino , Akio Nagano , Masahiko Watanabe , Tadasi Matsuura , Hirokazu Satoh , Fumiko Nomura , Katsuyuki Mitomo
发明人： Akihiro Hino , Akio Nagano , Masahiko Watanabe , Tadasi Matsuura , Hirokazu Satoh , Fumiko Nomura , Katsuyuki Mitomo
IPC分类号： A61K49/00 , A61K39/395 , C07K16/00 , C07K16/28
CPC分类号： A61K51/1027 , A61K51/1093 , A61K51/1096 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K16/46 , C07K2317/24 , C12N15/02 , C12N15/85
摘要： An object of the present invention is to provide a radioactive metal anti-cadherin antibody which is highly accumulated specifically in cancer tissue. Another object is to provide a cancer therapeutic agent having high anti-cancer effect and safety and a cancer diagnostic agent. The radioactive metal-labeled anti-cadherin antibody is obtained by binding a radioactive metallic element to an anti-cadherin antibody via a metal-chelating reagent.
摘要翻译： 本发明的目的是提供一种在癌组织中高度积累的放射性金属抗钙粘蛋白抗体。 另一个目的是提供具有高抗癌作用和安全性的癌症治疗剂和癌症诊断剂。 放射性金属标记的抗钙粘蛋白抗体是通过金属螯合剂将放射性金属元素与抗钙粘蛋白抗体结合而获得的。
-
公开(公告)号：US20090148425A1
公开(公告)日：2009-06-11
申请号：US12091686
申请日：2006-10-27
CPC分类号： C12N15/86 , A61K38/36 , A61K38/37 , A61K48/0058 , C12N2740/15043 , C12N2830/008
摘要： The present invention provides agents for treating blood coagulation abnormalities, which contain as an active ingredient a lentiviral vector carrying a blood coagulation factor gene operably linked to a promoter which induces platelet-specific expression. Agents for treating hemophilia A or hemophilia B are provided by application of the gene encoding Factor VIII or Factor IX. Blood coagulation abnormalities can be treated by gene therapy by infecting hematopoietic stem cells or such with the therapeutic agents of the present invention.
摘要翻译： 本发明提供了用于治疗血液凝固异常的药剂，其包含作为活性成分的携带凝血因子基因的慢病毒载体，所述凝血因子基因可操作地连接于诱导血小板特异性表达的启动子。 通过应用编码因子VIII或因子IX的基因提供治疗血友病A或血友病B的药剂。 可以通过用本发明的治疗剂感染造血干细胞的基因治疗来治疗血液凝固异常。
-
公开(公告)号：US09328160B2
公开(公告)日：2016-05-03
申请号：US13882453
申请日：2011-10-28
申请人： Keisuke Ishii , Keiko Katsumi , Tadashi Matsuura , Yukio Sudo , Katsuyuki Mitomo , Katsushi Kouda
发明人： Keisuke Ishii , Keiko Katsumi , Tadashi Matsuura , Yukio Sudo , Katsuyuki Mitomo , Katsushi Kouda
CPC分类号： C07K16/18 , A61K47/6849 , A61K2039/505 , C07K16/2896 , C07K2317/77
摘要： It is an object of the present invention to provide an anti-cadherin antibody having a high internalization capacity and provide an anti-cadherin antibody-drug conjugate that effectively kills cadherin-expressing cancer cells with the use of such antibody. The present invention provides an anti-cadherin antibody which recognizes a cadherin domain 1 (EC1) of cadherin and exhibits a high internalization capacity.
摘要翻译： 本发明的目的是提供具有高内化能力的抗钙粘蛋白抗体，并提供使用这种抗体有效杀死表达cadherin的癌细胞的抗钙粘蛋白抗体 - 药物偶联物。 本发明提供一种抗钙粘蛋白抗体，其识别钙黏着蛋白的钙粘蛋白结构域1（EC1）并表现出高的内化能力。
-
公开(公告)号：US20160058883A1
公开(公告)日：2016-03-03
申请号：US14390734
申请日：2012-04-04
申请人： Keisuke ISHII , Katsuyuki MITOMO , Katsushi KOUDA , Fumiko NOMURA , Yoko KAYUKAWA , Tadashi MATSUURA
发明人： Keisuke ISHII , Katsuyuki MITOMO , Katsushi KOUDA , Fumiko NOMURA , Yoko KAYUKAWA , Tadashi MATSUURA
CPC分类号： A61K47/6855 , A61K47/6851 , A61K47/6879 , A61K47/6889 , C07K16/28 , C07K16/30 , C07K16/3015 , C07K2317/565
摘要： It is an object of the present invention to provide a drug conjugate comprising an anti-CDH3 antibody that efficiently kills cancer cells expressing CDH3. According to the present invention, there is provided an immune complex formed by binding an antibody against CDH3 or a fragment thereof having CDH3 binding ability to a chemotherapeutic agent.
摘要翻译： 本发明的目的是提供一种药物结合物，其包含有效杀死表达CDH3的癌细胞的抗CDH3抗体。 根据本发明，提供了通过将针对CDH3的抗体或其与化疗剂具有CDH3结合能力的片段结合的免疫复合物。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.019 秒)
